Although there appears to be widespread support of evidence-based medicine as a
basis for rational prescribing, the challenges to it are signilicant and often
justified. A multitude of factors other than evidence drive clinical
decision-making, including patient preferences and social circumstances,
presence of diseasedrug and drug-drug interactions, clinical experience,
competing demands from more pressing clinical conditions, marketing and
promotional activity, and systemlevel drug policies.
SackettDL,
StraussSE,
RichardsonWS,
RosenbergW,
HaynesRB.
Evidence-based medicine: how to practice and teach EBM.
3rd ed.Edinburgh: Churchill
Livingstone, 2005.
2.
JuurlinkD,
MamdaniM,
LeeDet al.
Rates of hyperkalemia after ublication of the randomized
aldactone evaluation study. N Engl J Med2004;351:543–51.
3.
LevyAR,
O'BrienBJ,
SellorsC,
GrootendorstP,
WillisonD.
Coding ccuracy of administrative drug claims in the Ontario
Drug Benefit database. Can J Clin Pharmacol2003;10:67–71.
ShepherdJ,
CobbeSM,
FordIet al.
Prevention of coronary heart isease with pravastatin in men
with hypercholesterolemia. N Engl J Med1995;333:1301–8.
6.
The 4S Investigators.
Randomised trial of cholesterol lowering in 4444 patients
with coronary heart disease: the Scandinavian Simvastatin Survival Study
(4S). Lancet1994;344:1383–9.
7.
JonesP,
KafonekS,
LauroraI,
HunninghakeD.
Comparative dose fficacy study of atorvastatin versus
simvastatin, pravastatin, lovastatin, and fluvastatin in patients with
hypercholesterolemia (the CURVES study). Am J
Cardiol1998;81:582–7.
ZhouZ,
RahmeE,
PiloteL.
Are statins created equal? Evidence from randomized trials of
pravastatin, simvastatin, and atorvastatin for ardiovascular disease
prevention. Am Heart J2006;151:273–81.
10.
SalisburyC,
BosanquetN,
WilkinsonE,
BosanquetA,
HaslerJ.
The mplementation of evidence-based medicine in general
practice prescribing. Br J Gen Pract1998;48:1849–52.
11.
MuijrersPE,
GrolRP,
SijbrandijJ,
JanknegtR,
KnottnerusJA.
Differences in prescribing between GPs: impact of the
cooperation with harmacists and impact of visits from pharmaceutical
industry epresentatives. Fam Pract200522:624–30.
12.
PrenticeRL,
LangerR,
StefanickMLet al.
Combined postmenopausal hormone therapy and cardiovascular
disease: toward resolving the iscrepancy between observational studies and
the Women's Health Initiative clinical trial. Am J
Epidemiol2005;162:404–14.
13.
National Cholesterol Education
Program (NCEP). Detection, evaluation and treatment of high
blood cholesterol in adults (adult treatment panel III).
Bethesda, MD: US Department
of Health and Human Services, National Institutes of Health, National Heart,
Lung, and Blood Institute, 2002 (NIH
02-5215).
14.
RogersEM.
Diffusion of innovations. 5th ed.New York: Free
Press, 2003.
15.
MaxwellSR.
Evidence based prescribing.
BMJ2005;331:247–8
